ZYDUSLIFE - IntraDay Trade Analysis with Live Signals
Back to ListHere’s the intraday trading analysis for ZYDUSLIFE based on the provided parameters
IntraDay Trade Rating: 4.0
| Stock Code | ZYDUSLIFE | Market Cap | 1,09,282 Cr. | Current Price | 1,086 ₹ | High / Low | 1,094 ₹ |
| Stock P/E | 29.6 | Book Value | 235 ₹ | Dividend Yield | 0.09 % | ROCE | 16.6 % |
| ROE | 16.5 % | Face Value | 1.00 ₹ | DMA 50 | 957 ₹ | DMA 200 | 939 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.12 % | PAT Qtr | 1,806 Cr. | PAT Prev Qtr | 343 Cr. |
| RSI | 75.4 | MACD | 41.0 | Volume | 22,10,389 | Avg Vol 1Wk | 20,22,654 |
| Low price | 836 ₹ | High price | 1,094 ₹ | PEG Ratio | 0.94 | Debt to equity | 0.31 |
| 52w Index | 96.9 % | Qtr Profit Var | -35.8 % | EPS | 35.4 ₹ | Industry PE | 31.6 |
📈 Optimal Buy Price: 1,080 – 1,090 ₹ (near breakout zone)
🎯 Profit Exit Levels: 1,100 ₹ (short-term resistance), 1,120 ₹ (extended resistance)
🛑 Stop-Loss: 1,060 ₹ (below immediate support)
🔄 Intraday Exit Guidance: If already holding, consider exiting near 1,100–1,120 ₹ if RSI rises above 78 or MACD momentum slows. Current RSI (75.4) is overbought, while MACD (41.0) shows bullish momentum. Volume (22.1 lakh vs avg 20.2 lakh) is slightly above average, supporting intraday trades but caution is advised due to stretched RSI.
Positive
- Strong ROCE (16.6%) and ROE (16.5%) highlight efficiency.
- EPS of 35.4 ₹ supports valuation strength.
- Price trading above DMA 50 (957 ₹) and DMA 200 (939 ₹), confirming bullish trend.
- PEG ratio of 0.94 indicates reasonable growth valuation.
- Quarterly PAT remains strong at 1,806 Cr. despite decline.
- DII holdings increased (+0.12%), showing domestic support.
Limitation
- P/E (29.6) is slightly below industry average (31.6), but valuation remains stretched given profit decline.
- Quarterly PAT dropped from 343 Cr. to 1,806 Cr. with -35.8% variation, showing earnings volatility.
- FII holdings decreased (-0.11%), showing reduced foreign confidence.
- RSI (75.4) indicates overbought conditions, raising risk of profit booking.
- Debt-to-equity ratio of 0.31 adds moderate leverage risk.
- 52-week index at 96.9% reflects stock trading near highs, limiting upside.
Company Negative News
- Quarterly profit decline (-35.8%) raises concerns about sustainability.
- Reduced FII confidence (-0.11%).
Company Positive News
- Strong fundamentals with high ROCE and ROE.
- DII inflows (+0.12%) provide domestic support.
- EPS strength and PEG ratio highlight valuation resilience.
Industry
- Industry P/E at 31.6, slightly higher than ZYDUSLIFE’s valuation, suggesting sector premium.
- Pharma sector outlook remains positive with long-term demand growth.
Conclusion
⚖️ ZYDUSLIFE is a strong intraday candidate today. Fundamentals are solid with efficiency and valuation support, while technicals show bullish momentum. However, overbought RSI and profit decline limit upside. Best strategy is cautious entry near 1,080–1,090 ₹ with exits around 1,100–1,120 ₹. Tight stop-loss discipline is essential due to stretched momentum and earnings volatility.
Would you like me to extend this into a pharma sector overlay comparing peers like Sun Pharma and Dr. Reddy’s, or refine it into an intraday momentum setup for sharper entry/exit timing?